ProCE Banner Activity

CE / CME

Evolving Options for First-line and Switch Strategies in ART Selection

Multimedia
Led by Babafemi Taiwo, MBBS, a panel of experts discusses how the latest data inform their approach to managing challenging clinical scenarios, including a newly diagnosed transgender woman, a middle-aged patient re-engaging with care, and an older man with virologic suppression and extensive comorbidities.

Pharmacists : 1.25 contact {hours} ({0.125} CEUs)

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Released: June 15, 2018

Expiration: June 14, 2019

No longer available for credit.

Share

Faculty

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Monica Gandhi

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

Sally Hodder

Sally Hodder, MD

Executive Vice Chair and Director of AIDS Programs
Department of Medicine
New Jersey Medical School
University of Medicine & Dentistry of New Jersey
Newark, New Jersey

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grants provided by

AbbVie

Gilead

Janssen

Merck Human Health HIV

ViiV Healthcare

Target Audience

This program is intended for HIV specialists, infectious diseases clinicians, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the results of recent clinical studies on antiretroviral therapies, including new and emerging agents, in initial therapy and in switch strategies for HIV-infected patients
  • Effectively prevent or manage drug–drug interactions, adverse events, and other complications associated with HIV, antiretroviral therapy, and comorbidities including HCV infection
  • Apply strategies to reduce the risk or impact of resistance to antiretroviral therapy when managing HIV treatment

Disclosure

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director Disclosure

Program Director

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

Monica Gandhi, MD, MPH, has no real or apparent conflicts of interest to report.

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and Theratechnologies and funds for research support from Gilead Sciences, Merck, and ViiV.

Sally Hodder, MD

Executive Vice Chair and Director of AIDS Programs
Department of Medicine
New Jersey Medical School
University of Medicine & Dentistry of New Jersey
Newark, New Jersey

Sally Hodder, MD, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, and ViiV and that her spouse has ownership interest in Merck.

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV and funds for research support (paid to his institution) from GlaxoSmithKline and ViiV.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-18-073-H02-P. This program is designated for up to 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 15, 2018, through June 14, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in HIV management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.